Literature DB >> 8478007

Nucleotide substitutions at the -6 position in the promoter region of the factor IX gene result in different severity of hemophilia B Leyden: consequences for genetic counseling.

D Vidaud1, M Tartary, J M Costa, B R Bahnak, S Gispert-Sanchez, E Fressinaud, C Gazengel, D Meyer, M Goossens, J M Lavergne.   

Abstract

Mutations in the promoter region of the factor IX gene result in hemophilia B Leyden, which is characterized by considerable improvement in the disease after puberty. We have found that distinct nucleotide substitutions at the -6 position in the Leyden-specific (LS) region are associated with a different severity of hemophilia B. The proband (aged 2) from one family is a severe hemophiliac with factor IX activity (F.IXC) and antigen (F.IXAg) levels less than 1.0 U/dl. F.IXC and F.IXAg levels in two affected uncles are approximately 30% of normal levels. The LS region was targeted for analysis because the phenotypes suggested the inheritance of a factor IX Leyden gene. An abnormal TaqI digestion pattern was found in amplified DNA from the proband, and sequencing showed a G(-6) to C transversion that was linked to the disease in the family. In another family, two brothers (aged 8 and 9) suffer from mild hemophilia with F.IXC ranging from 7 to 10 U/dl and F.IXAg from 3 to 4 U/dl. They are the only documented members of the family with a bleeding tendency. Denaturing gradient gel electrophoresis on amplified fragments from one of the patient's genomic DNA corresponding to the 8 exons and flanking sequences of the factor IX gene suggested a defect only in a segment from the 5' region. This segment showed an altered TaqI digestion pattern, and sequencing demonstrated a G(-6) to A transition that was traced to the patient's mother and a grandmother. The different phenotypes associated with the G(-6) to A purine nucleotide transition compared with a G(-6) to C transversion provide evidence that this area is directly involved in the regulation of the human factor IX gene expression in vivo by binding of regulatory factors. The ability to predict that the conditions of a hemophilia B patient will improve with age has important implications for genetic counseling of the family. Therefore, the LS region should always be included when scanning the factor IX gene for mutations.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8478007     DOI: 10.1007/bf00218264

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  21 in total

1.  Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure.

Authors:  R D LANGDELL; R H WAGNER; K M BRINKHOUS
Journal:  J Lab Clin Med       Date:  1953-04

2.  Haemophilia B: database of point mutations and short additions and deletions--second edition.

Authors:  F Giannelli; P M Green; K A High; S Sommer; D P Lillicrap; M Ludwig; K Olek; P H Reitsma; M Goossens; A Yoshioka
Journal:  Nucleic Acids Res       Date:  1991-04-25       Impact factor: 16.971

3.  Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1 A.

Authors:  N P Pavletich; C O Pabo
Journal:  Science       Date:  1991-05-10       Impact factor: 47.728

4.  Evidence that descendants of three founders constitute about 25% of hemophilia B in the United States.

Authors:  R P Ketterling; C D Bottema; J A Phillips; S S Sommer
Journal:  Genomics       Date:  1991-08       Impact factor: 5.736

5.  Nucleotide sequence of the gene for human factor IX (antihemophilic factor B).

Authors:  S Yoshitake; B G Schach; D C Foster; E W Davie; K Kurachi
Journal:  Biochemistry       Date:  1985-07-02       Impact factor: 3.162

6.  Mutations in the catalytic domain of human coagulation factor IX: rapid characterization by direct genomic sequencing of DNA fragments displaying an altered melting behavior.

Authors:  O Attree; D Vidaud; M Vidaud; S Amselem; J M Lavergne; M Goossens
Journal:  Genomics       Date:  1989-04       Impact factor: 5.736

7.  Generation of single-stranded DNA by the polymerase chain reaction and its application to direct sequencing of the HLA-DQA locus.

Authors:  U B Gyllensten; H A Erlich
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

8.  Structural and functional basis of the developmental regulation of human coagulation factor IX gene: factor IX Leyden.

Authors:  S Hirosawa; J B Fahner; J P Salier; C T Wu; E W Lovrien; K Kurachi
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

9.  Why does the human factor IX gene have a G + C content of 40%?

Authors:  C D Bottema; M J Bottema; R P Ketterling; H S Yoon; R L Janco; J A Phillips; S S Sommer
Journal:  Am J Hum Genet       Date:  1991-10       Impact factor: 11.025

10.  A single base pair deletion in the promoter region of the factor IX gene is associated with haemophilia B.

Authors:  A J Hall; A Chuansumrit; I R Peake; P R Winship
Journal:  Thromb Haemost       Date:  1994-12       Impact factor: 5.249

View more
  3 in total

1.  Assessment of the F9 genotype-specific FIX inhibitor risks and characterisation of 10 novel severe F9 defects in the first molecular series of Argentinian patients with haemophilia B.

Authors:  Claudia Pamela Radic; Liliana Carmen Rossetti; Miguel Martín Abelleyro; Miguel Candela; Raúl Pérez Bianco; Miguel de Tezanos Pinto; Irene Beatriz Larripa; Anne Goodeve; Carlos Daniel De Brasi
Journal:  Thromb Haemost       Date:  2012-10-23       Impact factor: 5.249

2.  Functional expression of human mutant phosphofructokinase in yeast: genetic defects in French Canadian and Swiss patients with phosphofructokinase deficiency.

Authors:  N Raben; R Exelbert; R Spiegel; J B Sherman; H Nakajima; P Plotz; J Heinisch
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

3.  A CpG mutational hotspot in a ONECUT binding site accounts for the prevalent variant of hemophilia B Leyden.

Authors:  Alister P W Funnell; Michael D Wilson; Benoit Ballester; Ka Sin Mak; Jon Burdach; Natisha Magan; Richard C M Pearson; Frederic P Lemaigre; Kathryn M Stowell; Duncan T Odom; Paul Flicek; Merlin Crossley
Journal:  Am J Hum Genet       Date:  2013-03-07       Impact factor: 11.025

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.